10-Q · May 12, 2026
Vyome Holdings, Inc. reported Q1 2026 results with significant declines in both revenue and net loss compared to the prior period. Revenue decreased to $31,591 from $198,581 in Q1 2025, yielding a net loss of $985,521…
Earnings analysis · 10-Q
HIND earnings analysis
Filed August 12, 2026 · Our reading of the company's report
The latest report
The supplied 10-Q excerpt does not include the condensed financial statements or MD&A, so current-quarter revenue, margins, EPS, balance-sheet changes, cash flow, segment performance, and quantitative guidance cannot be…
Read full summary
The supplied 10-Q excerpt does not include the condensed financial statements or MD&A, so current-quarter revenue, margins, EPS, balance-sheet changes, cash flow, segment performance, and quantitative guidance cannot be assessed. Management reported effective disclosure controls as of June 30, 2026 and no material internal-control changes during the quarter. Risk factors were unchanged from the 2025 Form 10-K filed March 18, 2026, supporting a neutral assessment rather than a directional earnings call.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Disclosure Controls Effective
Management concluded that disclosure controls and procedures were effective at the reasonable-assurance level as of June 30, 2026.
-
No Material Control Changes
The company reported that there were no changes during the quarter ended June 30, 2026 that materially affected, or were reasonably likely to materially affect, internal control over financial reporting.
What to watch
-
Existing Risk Profile Unchanged
The company stated that there were no material changes to the risk factors in Item 1A of its 2025 Form 10-K filed March 18, 2026; therefore, the filing does not provide evidence that prior risks have been reduced.
Management's outlook
No quantitative revenue or EPS outlook was provided in the supplied 10-Q text. The filing only states that no material changes were made to the risk factors in the 2025 Form 10-K.
Earlier filings 4
10-K · March 18, 2026
Vyome Holdings (formerly ReShape Lifesciences) completed its merger with Vyome on August 15, 2025 and is a clinical-stage specialty pharmaceutical company focused on repurposing FDA‑approved molecules for rare…
10-Q · November 14, 2024
ReShape Lifesciences improved top-line and margin performance in Q3 2024 with revenue of $2,292 (vs $2,155 in Q3 2023) and gross margin rising to ~62.8% from ~59.8%; operating loss narrowed to $(1,761) from $(3,880).…
10-K · April 1, 2024
ReShape Lifesciences reported 2023 revenue of $8.678M with a net loss of $11.387M, an improvement versus 2022’s $11.240M revenue and $46.214M net loss. The company received FDA approval for the Lap-Band 2.0 in December…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.